Skip to main content
Clinical Trials/NCT00584155
NCT00584155
Withdrawn
Phase 1

Evaluation of Lactated Ringers for Protection From Cisplatin Ototoxicity.

University of Oklahoma1 site in 1 countryJuly 2006

Overview

Phase
Phase 1
Intervention
Normal Saline and 0.3% ofloxacin
Conditions
Hearing Loss
Sponsor
University of Oklahoma
Locations
1
Primary Endpoint
Pre-treatment audiogram will be compared with the post treatment audiogram. The differences between the two will be calculated and compared to the differences in the opposite ear.
Status
Withdrawn
Last Updated
10 years ago

Overview

Brief Summary

The purpose of this study is to determine if Lactated Ringer's solution is effective in patients undergoing chemotherapy with cisplatin for head and neck cancer in regards to cisplatin-induced hearing loss.

Detailed Description

About one-third of people who have been given Cisplatin, as part of their chemotherapy treatment, develop hearing loss. The purpose of this study is to determine if some degree of hearing loss can be prevented by use of Lactated Ringer's solution in the middle ear. To study this, patients will use drops in their ears; Lactated Ringer's will be placed in one ear and an inactive saline solution will be placed in the other. Ofloxacin, an eardrop antibiotic will be placed in each ear at the same time. Each participant will receive a hearing evaluation before each dose of Cisplatin and another evaluation 2 to 4 weeks after the final treatment.

Registry
clinicaltrials.gov
Start Date
July 2006
End Date
June 2010
Last Updated
10 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dini Chissoe

Study Coordinator

University of Oklahoma

Eligibility Criteria

Inclusion Criteria

  • Patients with cancer to be treated with cisplatin.
  • Patients expected to receive a minimum of 3 rounds of chemotherapy.
  • Patients receiving a minimum dose of cisplatin of 70 mg/m2

Exclusion Criteria

  • Patients who have had middle ear surgery.
  • Patients who have active external or middle ear disease
  • Patients who have preceding pure tone average of \>40 dB HL

Arms & Interventions

1

Each patient will receive a bottle containing normal saline and 0.03% ofloxacin.

Intervention: Normal Saline and 0.3% ofloxacin

2

Each patient will receive a bottle containing Lactated Ringer's solution and 0.03% ofloxacin.

Intervention: Lactated Ringer's with 0.03% Ofloxacin

Outcomes

Primary Outcomes

Pre-treatment audiogram will be compared with the post treatment audiogram. The differences between the two will be calculated and compared to the differences in the opposite ear.

Time Frame: Patients will be enrolled in the study for 4-6 weeks from the initiation of therapy

Study Sites (1)

Loading locations...

Similar Trials